RecruitingPhase 1NCT07310420

A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer

Phase 1 Single-arm, Open-label, Multicenter Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in 2 Parallel Cohorts of Premenopausal Women With Early-stage and Advanced Hormone Receptor-positive (HR+) Breast Cancer

Sponsor

TerSera Therapeutics LLC

Enrollment

176 participants

Start Date

Oct 30, 2026

Study Type

INTERVENTIONAL

Conditions

Advanced Breast Cancer Early Breast Cancer

Summary

The primary objective of this trial is to evaluate ovarian suppression following treatment with ZOLADEX 10.8 mg by luteinizing hormone (LH) within each cohort.

Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 55 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called ZOLADEX for people with advanced breast cancer. The study is currently recruiting participants at 11 locations. People eligible for this study include women aged 18 Years to 55 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGZOLADEX

Participants will receive ZOLADEX as a subcutaneous (SC) injection on Day 1 (Week 1), and Day 85 (Week 12) for a total of 2 treatments.

Locations(23)

Genesis Cancer and Blood Institute

Hot Springs, Arkansas, United States

MedStar Heart & Vascular Institute (MHVI) - MedStar Washington Hospital Center

Washington D.C., District of Columbia, United States

Cancer Centers of Florida

Ocoee, Florida, United States

University Cancer & Blood Center, LLC

Athens, Georgia, United States

Summit Cancer Care

Savannah, Georgia, United States

NorthShore University Health System - Evanston Hospital

Evanston, Illinois, United States

NorthShore University HealthSystem - Evanston Hospital

Evanston, Illinois, United States

Duly Health and Care

Lisle, Illinois, United States

Orchard Healthcare Research

Skokie, Illinois, United States

Springfield Clinic - The Cancer Center

Springfield, Illinois, United States

Ochsner Medical Center (OMC)

New Orleans, Louisiana, United States

Profound Research LLC at Michigan Hematology and Oncology Consultants

Royal Oak, Michigan, United States

St. Vincent Frontier Cancer Center (SVFCC) - Billings (Frontier Cancer Center and Blood Institute)

Billings, Montana, United States

San Juan Oncology Associates

Farmington, New Mexico, United States

New York Oncology Hematology - Amsterdam Cancer Center

Amsterdam, New York, United States

Chelsea Medical Center at Mount Sinai

New York, New York, United States

Montefiore Medical Center

The Bronx, New York, United States

Clinical Research Alliance Inc

Westbury, New York, United States

Cleveland Clinic Foundation

Cleveland, Ohio, United States

The Mark H. Zangmeister Center-Mid Ohio Oncology/Hematology, Inc.

Columbus, Ohio, United States

St. Luke's University Health Network

Bethlehem, Pennsylvania, United States

Guthrie Medical Group

Sayre, Pennsylvania, United States

Oncology Consultants PA

Houston, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07310420

Related Trials

A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)

NCT075410791 location

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

NCT0612028363 locations